Lumiracoxib is a selective COX-2 inhibitor, a non-steroidal anti-inflammatory drug (NSAID) previously utilized for the management of acute and chronic pain. In pharmaceutical research and development,… Read more
Lumiracoxib is a selective COX-2 inhibitor, a non-steroidal anti-inflammatory drug (NSAID) previously utilized for the management of acute and chronic pain. In pharmaceutical research and development, analytical laboratories require high-quality materials to ensure precise method validation and stringent quality control. This collection provides essential reference standards, including the Lumiracoxib active pharmaceutical ingredient (API), its known metabolites such as Lumiracoxib-acyl-β-D-glucuronide, and specific process-related impurities like N-nitroso Lumiracoxib. Additionally, stable isotope labelled compounds, such as deuterated Lumiracoxib, are available to serve as internal standards for mass spectrometry-based quantitative analysis. These reference materials support rigorous impurity profiling and metabolic studies, allowing researchers to accurately identify and quantify trace components within drug products, thereby maintaining compliance with regulatory standards throughout the analytical testing lifecycle.